Visión generalGráficoNoticiasTraderScreen

Morgan Stanley Call 37.5 SDZ 20.1.../  DE000MG2UMN9  /

Stuttgart
11/11/2024  12:17:48 Diferencia- Bid22:00:38 Ask22:00:38 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
0.450EUR - -
Volumen de oferta: -		 -
Tamaño/ Volumen/ Formato de Ask: -		 SANDOZ GROUP N 37.50 CHF 20/12/2024 Call
GlobeNewswire 12/08 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire 08/08 Sandoz reports second-quarter sales and half-year 2024 results
GlobeNewswire 25/07 Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire 01/07 FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire 22/05 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire 07/05 Sandoz reports first quarter 2024 sales
GlobeNewswire 30/04 Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire 30/04 Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire 22/04 Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire 21/03 Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire 13/03 Sandoz reports fourth quarter 2023 sales and full-year 2023 results
GlobeNewswire 05/03 Sandoz receives FDA approval for first and only denosumab biosimilars
GlobeNewswire 05/03 Sandoz announces nominations to the Board of Directors and leadership change
GlobeNewswire 04/03 Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire 29/02 Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire 01/02 Sandoz announces changes in the Board of Directors
GlobeNewswire 31/01 Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire 22/01 Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire 21/11/2023 Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
GlobeNewswire 10/11/2023 Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center ...
GlobeNewswire 08/11/2023 Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
GlobeNewswire 26/10/2023 Sandoz successfully issues CHF 750 million in inaugural bonds
GlobeNewswire 24/10/2023 Sandoz reports year-to-date sales for the first nine months of 2023
GlobeNewswire 04/10/2023 OTC Markets Group Welcomes Sandoz Group AG to OTCQX
TeleTrader 04/10/2023 Sandoz seals spin-off from Novartis, starts trading